CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the Company's management will participate in the following upcoming investor conferences. Citi's 2026 Global Healthcare Conference Format: One-on-one meetings Date: Tuesday, December 1, 2026 Location: Miami, Florida Piper Sandler 38th Annual Healthcare Conference Format: One-on-one meetings Date: Wednesday, December 2, 2026 Location: New York, New York ABOUT CERUS Cerus Corporation is dedicated so.
Turning Climate Warnings into Energy Action: Tuya Smart Showcases Its AI Energy Solutions at COP31PR NewswireANTALYA, Türkiye, Nov. 16, 2026ANTALYA, Türkiye,
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the Company's management will participate in and host one-on-one investor meetings at the 17th Annual Craig-Hallum Alpha Select Conference taking place in New York City on Tuesday, November 17. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company.
Shares of Cerus Corporation (NASDAQ: CERS - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating
A shift to higher-margin kit distribution and a successful red blood cell trial position Cerus for path to GAAP profitability.
Cerus Corporation ( CERS ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Timothy Lee - Head of Investor Relation Vivek Jayaraman - CEO, President & Director Kevin Green - VP of Finance & CFO Conference Call Participants Colin Clark - TD Cowen, Research Division Mark Massaro - BTIG, LLC, Research Division William Bonello - Craig-Hallum Capital Group LLC, Research Division Gabrielle Ingoglia - Cantor Fitzgerald & Co., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Cerus Corp. Q3 2026 Earnings Conference Call.
Cerus NASDAQ: CERS reported third-quarter product revenue growth of 10% year over year and reaffirmed its 2026 revenue outlook, while also announcing positive top-line results from its Phase III RedeS study of pathogen-reduced red blood cells.
Cerus' blood-safety system meets main goal in late-stage trial
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the third quarter ended September 30, 2026, and provided a business update. "Our solid performance in Q3 builds upon a strong first half of 2026 and increases our confidence as we approach year-end,” said Vivek Jayaraman, Cerus's president and chief executive officer. “Continued growth from our IFC business, core platelet franchise and international INT 200 rollout strengthens our foundation.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced positive topline results from the Phase 3 RedeS (NCT03037164) trial. “Over the past decade, pathogen reduction technology has become an integral component of the blood safety toolkit. The topline results from the RedeS study reinforce the potential to extend this established paradigm to red blood cell transfusions,” said Ross M. Fasano, MD, Professor of Pathology & Laboratory Medicine and Hematology at Emory.